Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd, an innovator in LAG-3 immunotherapy for cancer and autoimmune diseases, has partnered with the Centre for Human Drug Research to conduct a pioneering Phase I study of a new drug, IMP761, aimed at treating autoimmune diseases by restoring immune system balance. The trial, set to commence mid-2024, will enroll around 49 healthy volunteers to evaluate the drug’s safety and biological effects using a unique challenge model. This first-in-human study represents a significant stride in potentially altering the treatment landscape for autoimmune disorders.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
